FDA Approves Accrufer (ferric maltol) for the Treatment of Iron Deficiency in Adults

Article Link: FDA Approves Accrufer (ferric maltol) for the Treatment of Iron Deficiency in Adults

London, UK, 26 July 2019: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product…

Source: FDA New Drug Approvals